title: Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study.
abstract: The Southwest Oncology Group studied the response rate and toxicity of didemnin B (3.47 mg/m2 i.v. q 28 days) in patients with advanced renal cell carcinoma. There were no responses in 22 response evaluable patients. Toxicity was significant with 10 patients having grade 3 or 4 toxicity. Toxicity seen included nausea and vomiting, exacerbation of coronary artery disease, hyperglycemia, anorexia, diarrhea and hepatitis. Didemnin B was toxic but inactive in patients with renal cell treated at this dose.
authors.affiliation: University of Kansas Medical Center, Kansas City.
authors.forename: S A
authors.initials: SA
authors.lastname: Taylor
authors.forename: P
authors.initials: P
authors.lastname: Goodman
authors.forename: E D
authors.initials: ED
authors.lastname: Crawford
authors.forename: W J
authors.initials: WJ
authors.lastname: Stuckey
authors.forename: R L
authors.initials: RL
authors.lastname: Stephens
authors.forename: E R
authors.initials: ER
authors.lastname: Gaynor
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D047630:Depsipeptides; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C030051:didemnins